<!DOCTYPE html>
<!--
==============================================================================
           "GitHub HTML5 Pandoc Template" v2.1 — by Tristano Ajmone           
==============================================================================
Copyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:

- https://github.com/tajmone/pandoc-goodies

The CSS in this template reuses source code taken from the following projects:

- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):
  https://github.com/sindresorhus/github-markdown-css

- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):
  http://primercss.io/

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
The MIT License 

Copyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)
Copyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)
Copyright (c) 2017 GitHub Inc.

"GitHub Pandoc HTML5 Template" is Copyright (c) Tristano Ajmone, 2017, released
under the MIT License (MIT); it contains readaptations of substantial portions
of the following third party softwares:

(1) "GitHub Markdown CSS", Copyright (c) Sindre Sorhus, MIT License (MIT).
(2) "Primer CSS", Copyright (c) 2016 GitHub Inc., MIT License (MIT).

Permission is hereby granted, free of charge, to any person obtaining a copy
of this software and associated documentation files (the "Software"), to deal
in the Software without restriction, including without limitation the rights
to use, copy, modify, merge, publish, distribute, sublicense, and/or sell
copies of the Software, and to permit persons to whom the Software is
furnished to do so, subject to the following conditions:

The above copyright notice and this permission notice shall be included in all
copies or substantial portions of the Software.

THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR
IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE
AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER
LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,
OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE
SOFTWARE.
==============================================================================-->
<html>
<head>
  <meta charset="utf-8" />
  <meta name="generator" content="pandoc" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
  <title>Cellulitis MeG-CLS-051</title>
  <style type="text/css">
@charset "UTF-8";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,"Segoe UI",Helvetica,Arial,sans-serif,"Apple Color Emoji","Segoe UI Emoji","Segoe UI Symbol";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:""}.markdown-body hr::after{display:table;clear:both;content:""}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:" "}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:""}.markdown-body::after{display:table;clear:both;content:""}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}
  </style>
  <style type="text/css">code{white-space: pre;}</style>
  <!--[if lt IE 9]>
    <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js"></script>
  <![endif]-->
</head>
<body>
<article class="markdown-body">
<h2 id="cellulitis">Cellulitis</h2>
<h2 id="executive-summary"><em>Executive summary</em></h2>
<h2 id="introduction">Introduction</h2>
<p>The term cellulitis is commonly used to indicate a non-necrotizing inflammation of the skin and subcutaneous tissues, usually from acute infection. Cellulitis usually follows a breach in the skin, although a portal of entry may not be obvious; the breach may involve microscopic skin changes or invasive qualities of certain bacteria.</p>
<h2 id="target-users">Target Users</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Doctors</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Nurses</p>
</div></li>
</ul>
<h2 id="target-area-of-use">Target area of use </h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Ward</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Outpatient department</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Gate clinic</p>
</div></li>
</ul>
<h2 id="key-areas-of-focusnew-additionschanges">Key areas of focus/new additions/changes</h2>
<p>These guidelines addresses the management of cellulitis in adults and children.</p>
<h2 id="limitations">Limitations</h2>
<p>Patient with complicated cellulitis associated with compartment syndrome or necrosis must be referred to a surgeon.</p>
<h2 id="presenting-symptoms-and-signs">Presenting symptoms and signs</h2>
<p>Nonpurulent cellulitis is associated with the 4 cardinal signs of infections, as follows:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Erythema</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Pain</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Swelling</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Warmth</p>
</div></li>
</ul>
<p>The follow findings suggest severe infection:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Malaise</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Chills</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Fever and toxicity</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Circumferential cellulitis</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Lymphangitic spread (red lines streaking away from the area of infection)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Crepitus</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Pain disproportionate to examination findings</p>
</div></li>
</ul>
<h2 id="examination-findings">Examination findings</h2>
<p>The involved site(s) is/are red, hot, swollen and tender. The leg is the most common site. Tinea pedis lesions may be the sites of entry</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Regional lymphadenopathy may be present</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Malaise, chills, fever, and toxicity may be present</p>
</div></li>
</ul>
<p>Skin infections without associated drainage, penetrating trauma, eschar, or abscess is most likely caused by streptococci; on the other hand<strong>, <em>S aureus</em></strong>, often community acquired methicillin-resistant <em>S aureus</em> (MRSA), is the most likely pathogen when these factors are present.</p>
<p>Perianal cellulitis is usually observed in children with perianal fissures; it is characterized by <strong>perianal erythema</strong> and <strong>pruritis, purulent secretions</strong>, <strong>painful defecation</strong> and <strong>blood in stools</strong></p>
<p>Cellulitis characterized by violet colour and bullae suggests more serious or systemic infection with organisms such as <em>V. vulnificus</em> or <em>S. pneumoniae.</em></p>
<p>Lymphangitic spread (red lines streaking away from area of infection), crepitus, .and hemodynamic instability are indications of severe infection, requiring more aggressive treatment.</p>
<p>Circumferential cellulitis or pain that is disproportional to examination findings should prompt consideration of severe soft tissue infection</p>
<p><strong><a href="https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540402/all/Orbital_Cellulitis">Periorbital</a> (preseptal) cellulitis</strong> is potentially serious and merits an ophthalmology consultation and a CT scan to exclude an orbital infection</p>
<p><strong><span class="underline">Indication for referral for emergent surgical evaluation</span></strong> are as follows:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Violaceous bullae</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Cutaneous haemorrhage</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Skin sloughing</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Skin anaesthesia</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Rapid progression</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Gas in the tissue (crepitus)</p>
</div></li>
</ul>
<h2 id="differential-diagnoses">Differential Diagnoses</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Erysipelas (more superficial with sharply demarcated borders)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Thrombophlebitis</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p><a href="https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540378/all/Necrotizing_Fasciitis">Necrotizing fasciitis</a></p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Erythroderma</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Panniculitis</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Pyoderma</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Dermatitis</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Allergic reactions</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Drug reaction</p>
</div></li>
</ul>
<h2 id="investigations">Investigations</h2>
<p>Generally no work-up is required in uncomplicated cases of cellulitis.</p>
<p>For patients with cellulitis who have signs and symptoms of systemic inflammatory response, do:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>FBC</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Creatinine and Bicarbonate</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Aspirate gram stain and culture (purulent cellulitis only)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Blood culture should be performed for serious infections to pinpoint the etiology</p>
</div></li>
</ul>
<div data-custom-style="List Paragraph">
<p>Blood cultures are only positive in 5-15 % of patients with cellulitis)</p>
</div>
<div data-custom-style="List Paragraph">
<blockquote>
<p>Blood cultures are also indicated in special populations (immunosuppressed, severe post-surgical wounds).</p>
</blockquote>
</div>
<h2 id="management">Management </h2>
<h3 id="management-at-the-gate-clinic">Management at the Gate Clinic</h3>
<p>Patients with cellulitis should be referred to OPD for evaluation by a doctor.</p>
<h3 id="management-in-opd-or-on-the-ward">Management in OPD or on the ward</h3>
<p>Management of cellulitis should include elevation of the affected area and treatment of underlying conditions.</p>
<p>Many patients with cellulitis have underlying conditions that predispose them to developing recurrent cellulitis (these include tinea pedis, lymphedema, and chronic venous insufficiency). In such patients, treatment should be directed at both the infection and the predisposing condition if modifiable. As an example, patients with oedema may benefit from treatment with compressive stockings and diuretic therapy.</p>
<p>Consider in-patient care when there is:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>An elevated creatinine level</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>A low serum bicarbonate level</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Systemic signs of toxicity (e.g. fever &gt; 38°C, hypotension, or sustained tachycardia)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Rapid progression of erythema</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Progression of clinical findings after 48 hours of oral antibiotic therapy</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Inability to tolerate oral therapy</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Proximity of the lesion to an indwelling medical device (e.g. prosthetic joint or vascular graft)</p>
</div></li>
</ul>
<h3 id="nonpurulent-cellulitis">Nonpurulent cellulitis</h3>
<p>Patients with nonpurulent cellulitis (e.g. cellulitis with no purulent drainage or exudate and no associated abscess) should be managed with empiric therapy for infection due to beta-hemolytic streptococci and methicillin-susceptible <span data-custom-style="Emphasis">Staphylococcus aureus</span>. Common options for mild infections are:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Cloxacillin 25 mg/kg/dose (max. 500 mg) PO QDS</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Amoxicillin/Clavulanate 625 – 875 mg PO BD</p>
</div></li>
</ul>
<p>For patients with penicillin allergies:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Azithromycin 10 mg/kg (max. 500 mg) PO OD for 3 days, or</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Clindamycin 150 – 300 mg PO QDS (3 – 6 mg/kg/dose in children)</p>
</div></li>
</ul>
<p>In patients with moderately severe infection, intravenous antibiotics options include:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>IV Cloxacillin 1 – 2 g QDS</p>
</div></li>
</ul>
<p>For severe infections:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>IV Ceftriaxone 1 – 2 g OD (children 50 – 80 mg/kg OD)</p>
</div></li>
</ul>
<h3 id="purulent-infection"><span data-custom-style="h23"><strong>Purulent infection</strong></span></h3>
<p>Purulent infection refers to presence of a drainable abscess <span data-custom-style="Strong">or</span> cellulitis associated with purulent drainage in the absence of drainable abscess. Any infection involving purulence is potentially attributable to <span data-custom-style="Emphasis">MRSA</span>, which should be reflected in the choice of empiric antimicrobial therapy.</p>
<p><strong>Incision and drainage</strong> of abscess is indicated for all purulent infections and is sufficient for <strong>mild infections.</strong></p>
<p>For moderate infections, options for oral antibiotics include the following:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Doxycycline 100 mg PO BD (non-pregnant adults only), or</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Trimethoprim-sulfamethoxazole 24 mg/kg/dose (max. 960 mg) PO BD</p>
</div></li>
</ul>
<p>Once microorganisms are identified based on cultures, treatment is tailored to the patient’s need. The most common organism are staphylococcal and streptococcal strains.</p>
<h3 id="duration-of-therapy">Duration of therapy</h3>
<p>The appropriate duration of therapy for treatment of skin and soft tissue infection depends on the nature of the clinical presentation, and the clinical response should guide duration of therapy.</p>
<p>Patients with mild infection who receive outpatient management with oral antibiotic therapy should have repeat evaluation after 48 hours to verify clinical response.</p>
<p>Patients with MRSA responsive to oral therapy are typically treated for 5 days; treatment may be extended up to 14 days where there is severe infection, slow response to therapy, or immunosuppression. Lack of response may be due to infection with resistant organism(s), inadequate adherence, or presence of a deeper, more serious infection than previously realized.</p>
<p>Patients with infection warranting parenteral therapy (in the absence of bacteraemia or involvement beyond soft tissue) are typically treated for a total duration of 5 to 14 days. Once there are signs of clinical improvement with no evidence of systemic toxicity, antibiotics may be transitioned from parenteral to oral therapy.</p>
<p>For patients with abscess that was detected radiographically, follow-up imaging may be useful for assessing response to therapy.</p>
<h2 id="key-issues-for-nursing-care">Key Issues for Nursing care</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Ensure that patient get adequate bed rest: Passive exercise can reduce the associated complications</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Limb elevation is important to reduce oedema</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Pressure area care</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Cleaning any skin breaks carefully and monitoring for signs of infection</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Advise on basic skin care and avoidance of predisposing factors where possible</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Advise on avoidance of skin damage by wearing appropriate protective equipment when taking part in work or sport.</p>
</div></li>
</ul>
<h2 id="references">References</h2>
<p><a href="https://www.uptodate.com/contents/cellulitis-and-skin-abscess-in-adults-treatment/abstract/1">Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.</a></p>
<p><a href="https://www.uptodate.com/contents/cellulitis-and-skin-abscess-in-adults-treatment/abstract/2">Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis 2014; 59:147.</a></p>
<p><a href="https://www.uptodate.com/contents/cellulitis-and-skin-abscess-in-adults-treatment/abstract/3">Raff AB, Kroshinsky D. Cellulitis: A Review. JAMA 2016; 316:325.</a></p>
<p><a href="https://www.uptodate.com/contents/cellulitis-and-skin-abscess-in-adults-treatment/abstract/4">Halilovic J, Heintz BH, Brown J. Risk factors for clinical failure in patients hospitalized with cellulitis and cutaneous abscess. J Infect 2012; 65:128.</a></p>
<p>Herchline TE. Cellulitis. Medscape 2018. Available from: <a href="https://emedicine.medscape.com/article/214222-overview"><span data-custom-style="Hyperlink">https://emedicine.medscape.com/article/214222-overview</span></a></p>
<p>John Hopkins ABX guide for cellulitis</p>
<table>
<thead>
<tr class="header">
<th><strong>Written by:</strong></th>
<th>Name: Amie Secka</th>
<th>Date: 26 November 2018</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Reviewed by:</strong></td>
<td>Name: Fatai Akemokwe</td>
<td>Date: 28 January 2019</td>
</tr>
<tr class="even">
<td><strong>Version:</strong></td>
<td><strong>Change history:</strong></td>
<td><strong>Review due date:</strong></td>
</tr>
<tr class="odd">
<td>1.0</td>
<td>New document</td>
<td>31 January 2021</td>
</tr>
<tr class="even">
<td>1.1</td>
<td>Executive summary added</td>
<td>31 January 2021</td>
</tr>
<tr class="odd">
<td>Review Comments (<em>if applicable)</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
</article>
</body>
</html>
